Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
In the present study, the subtype specificity and species selectivity of the nonpeptide BIBP 3226, as well as its in vitro antagonism of neuropeptide Y (NPY)-mediated second messengers have been investigated. Radiolabeled NPY is potently displaced by BIBP 3226 [(R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenylmethyl]-D- arginine amide] on human Y1 receptor expressing Chinese hamster ovary-K1 cells (Ki = 0.47 +/- 0.07 nM). SK-N-MC human neuroblastoma cells (Ki = 5.1 +/- 0.5 nM) and the rat parietal cortex membranes (Ki = 6.8 +/- 0.7 nM). The interaction of BIBP 3226 with the Y1 receptor is stereoselective, because the (S)-enantiomer of the (R)-configured BIBP 3226 displays almost no affinity (Ki > 10,000 nM). In contrast, concentrations up to 10 microM BIBP 3226 do not displace [125I]NPY from the human Y2 receptor (neuroblastoma cell line SMS-KAN), the rabbit Y2 receptor (kidney) and the rat Y2 receptor (hippocampus). Functional antagonism could be shown for the human Y1 receptor: 0.1 microM BIBP 3226 antagonizes the NPY induced Ca++ mobilization (pKb = 7.5 +/- 0.17) as well as the NPY-mediated inhibition of cyclic AMP synthesis (pKb = 8.2 +/- 0.24) in SK-N-MC cells. In contrast, none of the formerly described putative antagonists PYX-2, [D-Trp32]NPY and benextramine could be characterized as high affinity Y1 receptor antagonists. The 18 amino acid NPY analog EXBP 68 Ile-Glu-Pro-Orn-Tyr-Arg-Leu-Arg-Tyr-NH2, cyclic (2,4'), (2',4')-diamide] displayed Y1-selective affinity with in vitro antagonistic properties (Ki = 0.33 +/- 0.04 nM and pKb = 8.4 +/- 0.07) in SK-N-MC cells. Therefore, BIBP 3226 is the first potent and subtype-selective nonpeptide Y1 receptor antagonist.
Wieland
H A
HA
Preclinical Research Department, Dr. Karl Thomae GmbH, Biberach, Germany.
Willim
K D
KD
Entzeroth
M
M
Wienen
W
W
Rudolf
K
K
Eberlein
W
W
Engel
W
W
Doods
H N
HN
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D000595:Amino Acid Sequence; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D006224:Cricetinae; D004285:Dogs; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D008969:Molecular Sequence Data; D009447:Neuroblastoma / Q000378:metabolism / Q000648:ultrastructure; D009478:Neuropeptide Y / Q000031:analogs & derivatives / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors* / Q000145:classification / Q000378:metabolism; D013237:Stereoisomerism; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured / Q000187:drug effects
C092926:BIBP 3226; C096170:EXBP 68; D009478:Neuropeptide Y; D010446:Peptide Fragments; D017476:Receptors, Neuropeptide Y; C079216:PYX 2; D001120:Arginine; D002118:Calcium